Company Is Investigating This Gilenya – PML Case To See Whether Brain Disease Might Be A Side Effect Of Its MS Drug
SUMMARY: We recently saw this news report on the website for the Multiple Sclerosis Society of Canada, “Case of PML reported in patient treated with Gilenya®”, and from from that article we get this more recent drug safety information:
Pharmaceutical company Novartis has reported a case of PML (progressive multifocal leukoencephalopathy) in an individual who had received Gilenya® (fingolimod) for more than 4 years for the treatment of relapsing-remitting multiple sclerosis (RRMS).
For a brief list of PML symptoms, we go back the the February 2015 MS Society of Canada news report about Gilenya:
Symptoms of PML can include: progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, changes in thinking, memory and orientation, confusion and personality changes.
We will continue to monitor the safety profile of this controversial Novartis MS drug and to watch for any more reports of PML in patients using Gilenya.
Gilenya (fingolimod) capsules were approved by the FDA in 2010 and by Health Canada in 2011.[Read this article in full at original source]
Strictly Confidential, No Obligation